vaccin
primari
method
prevent
influenza
respiratori
viru
infect
rvi
although
influenza
vaccin
abl
achiev
serolog
respons
allogen
hematopoiet
stem
cell
transplant
allohsct
recipi
clinic
benefit
still
uncertain
method
prospect
crosssect
studi
retrospect
analyz
effect
inactiv
trival
influenza
vaccin
preval
influenza
rvi
consecut
cohort
allohsct
adult
recipi
develop
rvi
flu
season
respiratori
virus
upperandor
lowerrespiratori
tract
specimen
test
use
multiplex
polymeras
chain
reaction
panel
assay
result
overal
diagnos
episod
influenza
rvi
allohsct
recipi
influenza
rvi
occur
nonvaccin
compar
vaccin
recipi
p
multivari
analysi
show
influenza
vaccin
associ
lower
preval
influenza
rvi
odd
ratio
p
multivari
risk
factor
analysi
lowerrespiratori
tract
diseas
lrtd
identifi
condit
associ
probabl
influenza
rvi
progress
influenza
vaccin
confid
interv
ci
p
highrisk
immunodefici
score
ci
p
influenza
vaccin
also
associ
lower
likelihood
influenzarel
hospit
admiss
vs
p
conclus
studi
show
influenza
vaccin
may
clinic
benefit
allohsct
recipi
virologicallyconfirm
rvi
term
lower
influenza
rvi
preval
slower
lrtd
progress
lower
likelihood
hospit
admiss
influenza
viru
signific
impact
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
patient
allohsct
lead
complic
rang
selflimit
upperrespiratori
tract
infect
lifethreaten
fatal
pneumonia
particular
threat
influenza
pose
allohsct
recipi
well
document
influenza
pandem
well
consecut
season
influenza
epidem
show
increas
risk
subsequ
bacteri
pneumonia
hospit
admiss
mechan
ventil
requir
mortal
vaccin
primari
method
prevent
influenza
infect
less
effect
immunocompromis
patient
healthi
individu
base
studi
analyz
serolog
respons
inactiv
influenza
vaccin
strongli
recommend
annual
patient
beyond
month
posttranspl
beyond
month
allohsct
without
graftversushost
diseas
gvhd
immunosuppress
commun
outbreak
howev
allohsct
recipi
respond
poorli
vaccin
onethird
allohsct
recipi
achiev
protect
influenza
antibodi
titer
obvious
limit
efficaci
vaccin
challeng
report
clinic
benefit
fact
clinic
evid
influenzainactiv
vaccin
effect
allohsct
limit
strategi
base
influenza
vaccin
higher
antigen
dose
multipl
vaccin
dose
adjuv
vaccin
might
improv
immun
respons
although
control
trial
perform
conduct
prospect
crosssect
observ
epidemiolog
studi
communityacquir
respiratori
viru
carv
respiratori
tract
diseas
rtd
allohsct
recipi
develop
upper
rtd
urtd
andor
lower
rtd
lrtd
symptom
transplant
patient
influenza
vaccin
statu
prospect
record
time
respiratori
viru
screen
studi
report
preval
influenza
rtd
accord
vaccin
statu
consecut
influenza
season
consecut
seri
allohsct
recipi
virologicallydocu
respiratori
viru
infect
rvi
prospect
crosssect
studi
rvi
adult
year
allohsct
recipi
conduct
spanish
transplant
center
whole
cohort
compris
consecut
allohsct
recipi
respiratori
symptom
prospect
screen
respiratori
virus
hospit
clinic
universitari
valencia
hcuv
decemb
may
hospit
universitari
la
fe
valencia
hlf
june
may
decemb
hcuv
may
hlf
implement
medic
informationeduc
recipi
caregiv
explain
detail
risk
rvi
context
immunosuppress
specif
inform
provid
includ
descript
respiratori
symptom
merit
urgent
notif
transplant
team
recommend
concern
screen
respiratori
virus
detail
avail
therapi
infecti
prevent
control
measur
patient
caregiv
telephon
number
oncal
h
emerg
condit
also
provid
local
ethic
committe
approv
studi
protocol
prospect
record
particip
clinic
biolog
characterist
time
carv
polymeras
chain
reaction
pcr
test
screen
includ
month
year
vaccin
influenza
vaccin
statu
flu
season
variabl
includ
immunodefici
score
index
isi
basel
immunodefici
grade
result
hospit
admiss
use
immunosuppress
drug
presenc
sign
symptom
acut
chronic
gvhd
transplant
characterist
aim
retrospect
compar
influenza
rtd
preval
vaccin
nonvaccin
particip
includ
recipientrv
episodevaccin
statu
flu
season
follow
select
algorithm
describ
figur
design
case
select
follow
first
inclus
criterion
retrospect
select
rvi
episod
irrespect
carv
detect
known
vaccin
status
next
step
divid
carv
episod
group
accord
vaccin
statu
rvi
episod
vaccin
unvaccin
correspond
flu
season
follow
recommend
world
health
organ
guidelin
exclud
carv
episod
take
place
outsid
flu
season
june
novemb
group
consid
decemb
may
recruit
period
accord
local
nation
epidemiolog
data
sinc
influenza
virus
circul
commun
third
step
exclud
episod
occur
day
stem
cell
infus
unvaccin
group
sinc
vaccin
given
recipi
period
first
record
influenza
vaccin
given
day
transplant
cohort
also
exclud
rvi
episod
baselin
diseas
relaps
occur
carv
episod
recipi
rvi
episod
flu
season
appli
follow
criteria
recipi
episod
carv
rvi
influenza
flu
season
comput
class
influenza
infect
season
recipi
episod
rvi
whose
vaccin
statu
chang
consecut
carv
rvi
episod
season
comput
twice
nonvaccin
group
vaccin
vaccin
group
recipi
develop
rvi
episod
caus
differ
influenza
virus
ie
influenza
b
differ
time
interv
flu
season
episod
comput
correspond
group
recipi
develop
influenza
viru
rvi
episod
season
influenza
viru
detect
first
episod
comput
final
recipi
develop
rvi
episod
caus
influenza
viru
comput
influenza
episod
season
annual
influenza
vaccin
recommend
patient
transplant
center
third
month
follow
allohsct
recipi
receiv
season
inactiv
trival
influenza
vaccin
accord
nation
health
vaccin
program
ran
novemb
februari
flu
season
patient
moder
sever
gvhd
time
vaccin
program
receiv
gammaglobulin
antithymocyt
globulin
rituximab
within
month
flu
vaccin
period
vaccin
administr
remain
physician
discret
urtd
defin
combin
upperrespiratori
tract
symptom
rhinorrhea
sinus
otiti
pharyng
well
posit
identif
carv
pcr
test
absenc
lowerrespiratori
tract
infect
symptom
indic
pulmonari
infiltr
chest
xray
comput
tomographi
ct
scan
radiolog
result
classifi
lrtd
possibl
probabl
confirm
previous
describ
probabl
episod
perform
bronchoscopi
patient
without
radiolog
proof
pulmonari
involv
defin
episod
urtd
lrtd
accord
european
confer
infect
recommend
acut
gvhd
diagnos
grade
accord
standard
criteria
patient
urtd
symptom
underw
nasopharyng
aspir
nasopharyng
swab
induc
sputum
test
bronchoalveolar
lavag
bal
perform
patient
lrtd
whenev
possibl
carv
test
bal
sampl
perform
realtim
pcr
multiplex
platform
describ
elsewher
detail
hcuv
sampl
test
realtim
pcr
use
luminex
xtag
rvp
fast
assay
luminex
molecular
diagnost
toronto
canada
hlf
clart
pneumovir
dna
array
assay
genomica
coslada
spain
perform
interpret
follow
manufactur
recommend
clart
pneumovir
dna
array
assay
differ
luminex
xtag
rvp
fast
assay
detect
influenza
c
viru
alphacoronaviru
viru
betacoronavirus
clart
pneumovir
identifi
new
influenza
primari
object
studi
compar
preval
influenza
urtd
andor
lrtd
clinic
characterist
among
vaccin
unvaccin
allohsct
recipi
secondari
endpoint
includ
identifi
risk
factor
influenza
rtd
progress
influenza
viru
urtd
lrtd
frequenc
compar
use
test
fisher
exact
test
categor
variabl
differ
median
compar
use
mannwhitney
u
test
univari
multivari
analys
associ
clinic
biolog
risk
factor
progress
influenza
lrtd
calcul
use
logist
regress
model
multivari
analys
variabl
paramet
estim
show
p
valu
univari
analysi
final
includ
report
exact
p
valu
p
valu
consid
statist
signific
data
analyz
spss
version
statist
packag
overal
allohsct
recipi
develop
episod
upperandor
lowerrespiratori
tract
symptom
screen
rvi
total
allohsct
recipi
develop
least
episod
virologicallydocu
rvi
account
episod
proven
rvi
accord
algorithm
select
figur
final
includ
allohsct
recipi
virologicallydocu
rvi
episod
flu
season
recipi
comput
twice
sinc
chang
vaccin
statu
cours
studi
season
within
consecut
season
thu
final
includ
characterist
recipi
case
accord
subject
vaccin
status
tabl
seasonallynonvaccin
allohsct
recipi
rvi
episod
seasonallyvaccin
recipi
rvi
episod
accomplish
select
criteria
comparison
purpos
particip
comput
rvi
episod
multipl
flu
season
specif
comput
rvi
episod
consecut
season
wherea
recipi
comput
episod
consecut
season
patient
clinic
biolog
characterist
time
rvi
episod
summar
tabl
accord
vaccin
status
expect
nonvaccin
group
significantli
higher
rate
condit
relat
poor
serolog
influenza
vaccin
respons
activ
gvhd
steroid
therapi
ongo
immunosuppress
therapi
hypogammaglobulinemia
significantli
overrepres
nonvaccin
group
compar
vaccin
group
vs
vs
vs
vs
respect
p
comparison
note
rate
low
total
lymphocyt
count
time
rvi
differ
cutoff
statist
differ
among
group
account
proven
influenza
rvi
episod
flu
season
recipi
median
time
onset
day
stem
cell
infus
rang
observ
higher
number
influenza
rvi
episod
n
n
shown
tabl
figur
togeth
season
repres
influenza
episod
flu
season
episod
limit
urtd
wherea
involv
lower
respiratori
tract
possibl
proven
lrtd
rate
hospit
directli
attribut
influenza
viru
episod
common
influenza
viru
subtyp
episod
remaind
subtyp
b
episod
case
influenza
b
detect
episodesampl
class
coinfect
observ
preval
influenza
rvi
significantli
higher
nonvaccin
compar
vaccin
group
p
statist
differ
even
higher
regard
influenza
lrtd
preval
nonvaccin
vs
vaccin
group
p
progress
rate
urtd
lrtd
recipi
influenza
rvi
nonvaccin
group
compar
vaccin
group
p
influenzarel
hospit
admiss
common
nonvaccin
group
compar
vaccin
group
vs
p
logist
regress
univari
multivari
analys
risk
factor
influenza
viru
respiratori
infect
progress
lrtd
shown
tabl
order
identifi
condit
associ
influenza
viru
infect
studi
evalu
recipientepisod
pair
multivari
analysi
identifi
flu
vaccin
main
factor
associ
reduc
risk
influenza
viru
infect
odd
ratio
confid
interv
ci
p
analyz
risk
factor
lrtd
progress
influenza
viru
infect
focus
analysi
multivari
analysi
identifi
independ
condit
associ
lrtd
progress
flu
vaccin
associ
lower
probabl
lrtd
progress
ci
p
contrast
highrisk
isi
score
predict
higher
probabl
influenza
viru
lrtd
progress
ci
p
studi
show
irrespect
flu
season
trival
influenza
inactiv
vaccin
given
allohsct
import
factor
associ
lower
preval
influenza
rvi
among
recipi
proven
carv
rvi
allohsct
recipi
influenza
rvi
multivari
analysi
show
influenza
vaccin
associ
lower
probabl
influenza
viru
progress
lrtd
also
observ
highrisk
isi
score
highli
predict
influenza
lrtd
progress
cohort
patient
although
studi
design
assess
vaccin
rate
popul
recipi
proven
carv
rvi
receiv
influenza
vaccin
flu
season
agre
prior
epidemiolog
studi
enquiri
vaccin
rate
rang
allohsct
howev
factor
merit
consider
interpret
report
vaccin
rate
detect
vaccin
recipi
prospect
respiratori
viru
survey
sinc
vaccin
may
lower
incid
carv
rvi
lower
propens
seek
medic
attent
test
howev
lack
consensu
across
current
guidelin
regard
time
condit
influenza
vaccin
administ
particular
immunosuppress
therapi
requir
treat
activeuncontrol
moderatetosever
gvhd
like
import
contributor
appar
low
vaccin
rate
scenario
physician
may
decid
defer
vaccin
thu
base
find
current
recommend
flu
vaccin
month
posttranspl
recipi
irrespect
immunosuppress
statu
select
cohort
half
unvaccin
recipi
develop
influenza
rvi
moder
sever
clinic
consequ
reflect
higher
hospit
admiss
lrtd
progress
rate
address
clinic
efficaci
influenza
vaccin
recipi
gvhd
corticosteroid
therapi
hypogammaglobulinemia
ongo
immunosuppress
use
compar
influenza
rvi
preval
vaccin
recipi
accord
presenc
absenc
condit
although
number
case
limit
find
statist
differ
regard
vaccin
recipi
without
gvhd
vs
respect
p
corticosteroid
vs
p
immunosuppress
vs
p
hypogammaglubulinemia
vs
p
fact
multivari
analysi
reveal
vaccin
statu
main
condit
associ
lower
influenza
rvi
preval
recipi
least
episod
carv
rvi
import
find
sinc
provid
clinic
evid
season
influenza
vaccin
could
clinic
benefici
allohsct
recipi
even
signific
number
vaccin
recipi
gvhd
use
immunosuppress
use
corticosteroid
although
serolog
vaccin
respons
recipi
poor
specul
vaccin
may
also
exert
cellularmedi
respons
influenza
vaccin
abl
mediat
peripher
blood
tcell
respons
character
product
cytokin
ifngamma
cell
patient
vaccin
month
transplant
vaccin
earlier
stem
cell
transpant
data
suggest
even
case
expect
serolog
respons
could
suboptim
allohsct
mo
gvhd
immunosuppress
use
corticosteroid
use
influenza
vaccin
could
elicit
clinic
benefit
cellularlymedi
effect
reduc
influenza
infect
preval
andor
sever
although
influenza
rvi
preval
vaccin
recipi
still
substanti
note
risk
factor
influenza
lrtd
progress
identifi
vaccin
condit
associ
reduc
rate
lrtd
progress
furthermor
vaccin
also
associ
lower
hospit
admiss
rate
given
find
specul
vaccin
could
mitig
sever
influenza
rvi
even
presenc
condit
relat
decreas
serolog
respons
anoth
relev
find
use
isi
score
stratifi
lrtd
progress
risk
influenza
rvi
even
analyz
episod
occur
day
stem
cell
infus
isi
develop
investig
md
anderson
cancer
center
predict
outcom
allohsct
recipi
respiratori
syncyti
virus
investig
demonstr
valu
predict
lrtd
progress
set
influenza
rvi
therefor
use
isi
could
appli
assess
need
prophylactictherapeut
intervent
sever
dose
influenza
vaccin
andor
high
dose
antivir
drug
prospect
studi
abbrevi
alc
absolut
lymphocyt
count
allohsct
allogen
hematopoiet
stem
cell
transplant
anc
absolut
neutrophil
count
atg
antithymocyt
globulin
basel
ig
basel
immunodefci
grade
ci
confid
interv
gvhd
graftversushost
diseas
hla
human
leucocyt
antigen
igg
immunoglobulin
g
immunosuppress
isi
immunodefici
score
index
log
regr
logist
regress
model
lrtd
lowerrespiratori
tract
diseas
ns
signific
nt
test
odd
ratio
rtd
respiratori
tract
diseas
rvi
respiratori
viru
infect
variabl
includ
final
multivari
model
sinc
includ
isi
score
regard
influenza
viru
epidemiolog
data
current
studi
influenza
rvi
case
occur
flu
season
data
accord
spanish
epidemiolog
data
influenza
preval
significantli
higher
hab
hab
compar
flu
season
hab
respect
observ
confirm
influenza
rvi
preval
allohsct
recipi
mimick
influenza
viru
preval
gener
popul
final
acknowledg
studi
import
limit
retrospect
natur
analys
small
sampl
size
somewhat
heterogen
vaccin
polici
cohort
select
method
addit
use
differ
pcr
method
differ
minim
analyt
perform
view
limit
spite
studi
strength
merit
consider
use
molecular
test
prospect
carv
survey
mirror
nation
epidemiolog
data
influenza
rvi
flu
season
provid
data
encompass
complet
flu
season
limit
distort
like
introduc
vaccin
coverag
variabl
season
conclus
provid
clinic
evid
influenza
vaccin
allohsct
associ
lower
preval
influenza
rvi
lower
sever
diseas
